Current Editions
Editor's Commentary
BioNTech gearing up to advance BNT327 to Phase III for triple-negative breast cancer after promising Phase II survival data
Product Development
Some firms are no longer making their latest funds their largest; others may follow
Editor's Commentary
Defense bill places biotech under national security umbrella
Politics, Policy & Law
Riskier bets deliver returns comparable to clinical counterparts
Finance
Product Development
How CEOs are managing through uncertainty, and why ‘boring’ naked mAbs are the smart move in one field
Editas, Beam report updates on sickle cell genetic therapies at this year’s ASH meeting
Data Byte
Plus: BridgeBio’s Attruby approved for ATTR-CM, PTC’s gene therapy for AADC deficiency, and Gilead withdrew Trodelvy for urothelial cancer
November meeting highlights also include a pair of firsts for rare genetic diseases, and label expansions for eight approved drugs
Discovery & Translation
BioCentury’s roundup of translational innovations also includes an Arkuda-J&J granulin gene therapy
Deals
Nvelop CEO Jeff Walsh will lead nChroma, which has $75M in new funding and a lead for HBV
Also in BioCentury’s Deals Report, a trio of biotech deals by GSK, and more
Finance
In BioCentury’s Venture Report: Fundings for Citryll, Angitia, Tasca, Veradermics and more
NewAmsterdam’s CETP readout leads to week’s largest follow-on
Biopharma Stock Performers
Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.
Product Development
Politics, Policy & Law
Management Tracks
BioCentury ISSN 1097-7201